Adherium Ltd. (AU:ADR)
ASX:ADR
Top Page
Adherium Ltd.
(Sydney:ADR)
Select Model
Select Model
Rating:41Neutral
Price Target:
AU$0.01
▲(0.00% Upside)
Action:ReiteratedDate:10/19/25
Adherium Ltd.'s overall score of 41 is driven primarily by its extremely weak financial performance, with deep losses, negative equity, and cash burn signaling high risk. Valuation concerns due to a negative P/E ratio further weigh on the score, while limited technical data provides no significant positive offset.
Positive Factors
Innovative Product Offering
Adherium's focus on smart inhaler technology positions it as a leader in digital health solutions, enhancing medication adherence and treatment outcomes, which is critical in the growing chronic respiratory disease market.
Negative Factors
Negative Revenue Growth
Declining revenue growth indicates challenges in market expansion and product adoption, which could hinder long-term profitability and competitive positioning in the medical devices industry.
Read all positive and negative factors
Positive Factors
Negative Factors
Innovative Product Offering
Adherium's focus on smart inhaler technology positions it as a leader in digital health solutions, enhancing medication adherence and treatment outcomes, which is critical in the growing chronic respiratory disease market.
Read all positive factors
Adherium Ltd. (ADR) vs. iShares MSCI Australia ETF (EWA)
Market Cap
AU$13.43M
Dividend YieldN/A
Average Volume (3M)1.17M
Price to Earnings (P/E)―
Beta (1Y)2.13
Revenue Growth-2.82%
EPS Growth32.47%
CountryAU
Employees40
SectorHealthcare
Sector Strength45
IndustryMedical - Devices
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding5,373,730,500
10 Day Avg. Volume107,278
30 Day Avg. Volume1,170,790
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)-0.76
Price to Sales (P/S)4.40
P/FCF Ratio-0.36
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.51
Revenue Forecast (FY)AU$22.37M
Adherium Ltd. Business Overview & Revenue Model
Company Description
Adherium Limited develops, manufactures, and supplies digital health technologies that address sub-optimal medication use in chronic diseases in New Zealand, Australia, Europe, North America, and Asia. The company offers Hailie, an asthma and chro...
How the Company Makes Money
Adherium generates revenue primarily through the sale of its smart inhaler devices and the associated software services. The company partners with pharmaceutical companies and healthcare providers to integrate its technology into their treatment r...
Adherium Ltd. Financial Statement Overview
Summary
Income Statement
15
Very Negative
Balance Sheet
10
Very Negative
Cash Flow
20
Very Negative
| Breakdown | TTM | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 1.12M | 817.24K | 840.98K | 3.19M | 529.00K | 401.00K |
| Gross Profit | 380.47K | 111.37K | 267.70K | 1.69M | -690.00K | -789.00K |
| EBITDA | -12.59M | -12.44M | -11.56M | -11.50M | -12.65M | -13.03M |
| Net Income | -12.76M | -12.68M | -10.22M | -9.86M | -10.04M | -15.04M |
Balance Sheet | ||||||
| Total Assets | 4.16M | 3.52M | 9.89M | 12.68M | 8.53M | 17.04M |
| Cash, Cash Equivalents and Short-Term Investments | 642.27K | 43.26K | 6.20M | 9.08M | 5.28M | 15.18M |
| Total Debt | 1.33M | 3.12M | 93.20K | 44.00K | 85.00K | 0.00 |
| Total Liabilities | 4.94M | 8.28M | 3.41M | 3.47M | 3.00M | 3.00M |
| Stockholders Equity | -787.24K | -4.76M | 6.48M | 9.21M | 5.54M | 14.04M |
Cash Flow | ||||||
| Free Cash Flow | -11.00M | -10.03M | -10.61M | -9.32M | -9.89M | -11.30M |
| Operating Cash Flow | -10.94M | -9.98M | -10.61M | -9.28M | -9.61M | -11.27M |
| Investing Cash Flow | -61.72K | -48.19K | -37.00 | -41.00K | -279.00K | -29.00K |
| Financing Cash Flow | 11.26M | 3.87M | 7.73M | 13.07M | 0.00 | 21.90M |
Adherium Ltd. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
54 Neutral | AU$50.82M | -9.32 | -417.72% | ― | -34.06% | 75.47% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
48 Neutral | AU$24.72M | -1.40 | -98.14% | ― | 14.84% | 39.64% | |
43 Neutral | AU$3.12M | -0.88 | -358.43% | ― | -30.80% | -38.95% | |
41 Neutral | AU$13.43M | -0.50 | 459.94% | ― | -2.82% | 32.47% | |
40 Underperform | AU$26.13M | -4.09 | -58.40% | ― | -7.20% | 28.70% |
* Healthcare Sector Average
AU:ADR
Adherium Ltd.
―
―
―
AU:UCM
Uscom Limited
0.01
>-0.01
-42.86%
AU:HMD
HeraMED Ltd.
0.04
0.03
193.33%
AU:AT1
Atomo Diagnostics Ltd.
0.03
<0.01
40.00%
AU:CBL
Control Bionics Ltd.
0.06
0.02
33.33%
Adherium Ltd. Corporate Events
Adherium Director George Baran Boosts Equity Stake Through Note Conversions and Option Exercises
Jan 8, 2026
Adherium Limited has disclosed substantial changes to director George Baran’s direct and indirect holdings following a series of share issues, option exercises, and conversions of convertible notes. Through Trudell Medical Limited and relate...
Adherium Director George Baran Converts Notes and Expands Equity Stake
Jan 5, 2026
Adherium director George Baran has significantly increased his indirect equity stake in the company through Trudell Medical Limited following the conversion of convertible notes into fully paid ordinary shares and the receipt of additional attachi...
Adherium Issues Over 554 Million New Shares and Lodges Cleansing Notice
Dec 31, 2025
Adherium Limited has issued 554,114,211 fully paid ordinary shares without a prospectus or disclosure document under the Corporations Act and has lodged a cleansing notice so these shares can be traded on the ASX without further disclosure. The co...
Adherium Seeks ASX Quotation for 80 Million New Shares
Dec 31, 2025
Adherium Ltd has applied to the ASX for quotation of 80 million new fully paid ordinary shares (code ADR), issued on 30 December 2025. The move significantly increases the company’s quoted share base and signals a fresh injection of equity c...
Adherium Issues 237 Million Unquoted Options Expiring in 2028
Dec 31, 2025
Adherium Ltd has issued 237,075,105 unquoted options, each exercisable at $0.02 and expiring on 5 December 2028, under its existing capital management arrangements. The substantial grant of long-dated, unquoted options, which are not intended to b...
Adherium Seeks ASX Quotation for 474 Million Newly Issued Shares
Dec 31, 2025
Adherium Ltd has applied to the ASX for quotation of 474,114,211 new fully paid ordinary shares (ASX code: ADR), issued on 29 December 2025. The substantial uplift in quoted securities expands the company’s listed equity base, potentially af...
Adherium Beats 2025 Hailie Smartinhaler Shipment Targets, Strengthening RPM Growth Platform
Dec 23, 2025
Adherium has surpassed its key calendar year 2025 shipment targets for its Hailie Smartinhaler platform, delivering more than 2,034 devices to Remote Patient Monitoring (RPM) patients and exceeding 4,666 total devices across all channels, ahead of...
Adherium Reports Significant Growth in Remote Patient Monitoring Revenues
Dec 15, 2025
Adherium Limited has reported substantial growth in its remote patient monitoring (RPM) subscription revenues, with a projected 103.1% increase quarter-on-quarter for Q2 FY26. The company’s strategic partnerships and clinic activations have ...
Adherium Ltd. Announces Director’s Increased Stake
Dec 12, 2025
Adherium Ltd. announced a change in the director’s interest, with Keven Gessner acquiring 4,000,000 fully paid ordinary shares and 4,000,000 unlisted options. This change, approved at the recent Annual General Meeting, signifies a strategic ...
Adherium Issues 19 Million Shares to Strengthen Market Position
Dec 8, 2025
Adherium Limited has issued 19,000,000 fully paid ordinary shares without disclosure to investors under the Corporations Act. The company confirms compliance with relevant provisions and states there is no excluded information to disclose. This mo...
Adherium Limited Issues 50 Million Unquoted Equity Securities
Dec 8, 2025
Adherium Limited has announced the issuance of 50 million unquoted equity securities, specifically options expiring on December 5, 2028, at an exercise price of $0.020. This move is likely to impact the company’s capital structure and could ...
Adherium Ltd. Issues 4 Million Unquoted Options
Dec 8, 2025
Adherium Ltd. announced the issuance of 4,000,000 unquoted options set to expire on July 31, 2026, with an exercise price of $0.005. This move is part of previously announced transactions and is not intended to be quoted on the ASX, potentially im...
Adherium Ltd. Announces Quotation of New Securities on ASX
Dec 8, 2025
Adherium Ltd. announced the quotation of 4,000,000 fully paid ordinary shares on the Australian Securities Exchange (ASX), effective December 5, 2025. This issuance is part of previously announced transactions, potentially enhancing the company...
Adherium Ltd. Announces Quotation of New Securities on ASX
Dec 8, 2025
Adherium Ltd. has announced the quotation of 15,000,000 fully paid ordinary securities on the Australian Securities Exchange (ASX), effective from December 4, 2025. This move is part of previously announced transactions and may enhance the company...
Adherium Partners with Allergy Partners to Expand Hailie® Smartinhaler® Deployment
Nov 28, 2025
Adherium Limited has announced a partnership with Allergy Partners to deploy its Hailie® Smartinhaler® technology across more than 100 clinics. This collaboration aims to enhance respiratory care on a large scale in the US and potentiall...
Adherium Issues New Shares to Strengthen Market Position
Nov 18, 2025
Adherium Limited has announced the issuance of 71,005,701 fully paid ordinary shares without disclosure under the Corporations Act 2001. The company has complied with all relevant legal provisions and there is no excluded information that needs to...
Adherium Ltd. Announces Quotation of New Securities on ASX
Nov 18, 2025
Adherium Ltd. has announced the quotation of 71,005,701 fully paid ordinary securities on the Australian Securities Exchange (ASX), effective November 14, 2025. This move is part of the company’s strategy to enhance its capital structure, po...
Adherium Limited’s AGM Results: All Resolutions Approved
Nov 18, 2025
Adherium Limited announced the successful outcome of its Annual General Meeting, where all resolutions, including a special resolution, were approved by shareholders. This development signifies strong shareholder support and could enhance Adherium...
Adherium Ltd. Navigates Challenges in Respiratory Care Market
Nov 17, 2025
Adherium Ltd. has released a presentation outlining its position in the respiratory care market. The announcement highlights the company’s strategic focus on developing medical devices, while acknowledging the inherent risks and uncertaintie...
Adherium Ltd. Announces Proposed Issue of 15 Million Securities
Nov 17, 2025
Adherium Ltd. announced a proposed issue of 15 million fully paid ordinary securities, set to be issued on November 25, 2025. This strategic move is likely aimed at raising capital to support the company’s ongoing operations and growth initi...
Adherium Engages Stralis Capital for Strategic Advisory and Equity Raising
Nov 17, 2025
Adherium Limited has engaged Stralis Capital Partners as its strategic and capital markets advisor to assist with capital management initiatives, including early exercise of options and potential equity capital raising. This partnership aims to en...
Adherium Raises $2.47 Million Through Share Issuance
Nov 11, 2025
Adherium Limited has successfully raised $2,472,505.205 through the issuance of fully paid ordinary shares following the exercise of 494,501,041 options. This capital raise, conducted without disclosure to investors under specific sections of the ...
Adherium Announces Director’s Interest Change
Nov 11, 2025
Adherium Limited has announced a change in the director’s interest, specifically involving George Baran, who has increased his indirect interest in the company. This change involves the conversion of options into fully paid ordinary shares a...
Adherium Ltd. Announces Quotation of Over 494 Million Securities on ASX
Nov 11, 2025
Adherium Ltd. has announced the quotation of a significant number of ordinary fully paid securities on the Australian Securities Exchange (ASX), totaling over 494 million shares. This move is likely to enhance the company’s capital structure...
Adherium Ltd. Issues Over 494 Million Unquoted Equity Securities
Nov 11, 2025
Adherium Ltd. has announced the issuance of a significant number of unquoted equity securities, totaling over 494 million options set to expire in November 2026. This strategic move is part of previously announced transactions, potentially impacti...
Adherium Issues New Shares to Strengthen Market Position
Oct 31, 2025
Adherium Limited has issued 62,666,668 fully paid ordinary shares without disclosure under Part 6D.2 of the Corporations Act 2001. The company confirms compliance with relevant provisions of the Corporations Act and states that no excluded informa...
Adherium Ltd Announces Director’s Change in Interest
Oct 31, 2025
Adherium Ltd has announced a change in the interest of its director, Louis Panaccio, involving the conversion of unlisted options into fully paid ordinary shares and the issuance of bonus options. This change reflects a strategic move in the compa...
Adherium Ltd. Expands Market Presence with New Securities Quotation
Oct 31, 2025
Adherium Ltd. has announced the quotation of 62,666,668 ordinary fully paid securities on the ASX, following the exercise of options and conversion of other convertible securities. This move is expected to bolster the company’s market presen...
Adherium Limited Issues Over 62 Million Unquoted Equity Securities
Oct 31, 2025
Adherium Limited has announced the issuance of a significant number of unquoted equity securities, totaling over 62 million options set to expire in November 2026. This move is part of a previously announced transaction and is not intended to be q...
Adherium Reports Strong Growth and Groundbreaking Study Results
Oct 31, 2025
Adherium Limited reported a significant 55% increase in device shipments for the quarter ending September 2025, driven by the launch of a new patient education call center and strong partnerships. The company also highlighted groundbreaking result...
Adherium Ltd. Issues Over One Million Unquoted Equity Securities
Oct 27, 2025
Adherium Ltd. has announced the issuance of over one million unquoted equity securities, specifically options set to expire in November 2026. This move is part of previously announced transactions and reflects the company’s ongoing efforts t...
Adherium Ltd. Announces Quotation of New Securities on ASX
Oct 27, 2025
Adherium Ltd. has announced the quotation of 1,004,372 ordinary fully paid securities on the Australian Securities Exchange (ASX), effective from October 21, 2025. This move signifies the company’s ongoing efforts to strengthen its financial...
Adherium Corrects Issued Options Notification
Oct 20, 2025
Adherium Limited announced a correction to a previous notification regarding the number of issued options due to an administrative error. This update, which affects the company’s unquoted equity securities, highlights the importance of accur...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.